1-3 of 3
Mariko Watanabe
Close
Sort by
Journal Articles

Inhibition of NF-κB Activation Augments the Effect of 5-Azacytidine On Acute Myeloid Leukemia Cell Line

Tomiteru Togano, MD, PhD, Makoto Nakashima, MS, Mariko Watanabe, PhD, Kazuo Umezawa, PhD, Toshiki Watanabe, MD, PhD, Masaaki Higashihara, M.D., PhD., Ryouichi Horie, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1369.
https://doi.org/10.1182/blood.V120.21.1369.1369
Published: 2012
Journal Articles

Dual targeting of transformed and untransformed HTLV-1–infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia

Mariko Watanabe, Takeo Ohsugi, Momoko Shoda, Takaomi Ishida, Shigemi Aizawa, Masae Maruyama-Nagai, Atae Utsunomiya, Shin Koga, Yasuaki Yamada, Shimeru Kamihira, Akihiko Okayama, Hiroshi Kikuchi, Kimiharu Uozumi, Kazunari Yamaguchi, Masaaki Higashihara, Kazuo Umezawa, Toshiki Watanabe, Ryouichi Horie
Journal: Blood
Blood (2005) 106 (7): 2462–2471.
https://doi.org/10.1182/blood-2004-09-3646
Published: 2005
Includes: Supplemental data
Journal Articles

The E1841K Mutation in MYH-9 of a Patient with May-Hegglin Anomaly Inhibits the Disassembly of Non-Muscle Myosin IIA (MYH-9) Responsible for the Phenotype of the Disease.

Koji Miyazaki, MD, PhD, Satoshi Komatsu, PhD, Mariko Watanabe, Naoya Nakadate, MD, PhD, Mitsuo Ikebe, PhD, Masaaki Higashihara, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 736.
https://doi.org/10.1182/blood.V104.11.736.736
Published: 2004